Noun:

পুন:পাতন, পালটান,

Verb:

পুন:পাতিত হত্তয়া,

relapsed's Usage Examples:

treatment of relapsed or refractory mycosis fungoides and Sézary disease.

It was approved in Japan in 2012, for the treatment of relapsed or refractory.

However, nine of these countries have relapsed and have not re-graduated.

name Besponsa, is an antibody-drug conjugate medication used to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

is approved by US FDA for the treatment of adult patients experiencing relapsed follicular lymphoma who have received at least two prior systemic therapies.

The trial evaluated 266 heavily-pretreated patients with relapsed and refractory multiple myeloma who had received at least two prior therapies.

mutation–positive relapsed or refractory acute myeloid leukemia (AML).

In November 2018, the FDA approved gilteritinib for treatment of adult patients with relapsed or.

name Adcetris) is an antibody-drug conjugate medication used to treat relapsed or refractory Hodgkin lymphoma (HL) and systemic anaplastic large cell.

medication used as a second-line treatment for Philadelphia chromosome-negative relapsed or refractory acute lymphoblastic leukemia.

follicular lymphoma in combination with chemotherapy, and as treatment for relapsed or refractory follicular lymphoma in combination with bendamustine chemotherapy.

are evaluating the drug in patients with relapsed or refractory Hodgkin’s and non-Hodgkin’s lymphoma and relapsed or refractory CD25-positive acute myeloid.

sold under the brand name Blenrep, is a medication for the treatment of relapsed and refractory multiple myeloma.

Phase I/II trials in relapsed/refractory follicular lymphoma have been completed in the United States.

Even high grade, aggressive, relapsed, or transformed FL may also be served with observation in patients who.

Loncastuximab tesirine is indicated for the treatment of adults with relapsed or refractory large B-cell lymphoma.

Acalabrutinib, approved in October 2017 for relapsed mantle cell lymphoma Zanubrutinib for mantle cell lymphoma.

Isatuximab is an anti-CD38 mAb intended to treat relapsed or refractory multiple myeloma.

Previous treatment options for multiply relapsed aggressive non-Hodgkin lymphoma had disappointing response rates.

marketed by Seattle Genetics and Millennium/Takeda) was approved for relapsed HL and relapsed sALCL by the FDA on August 19, 2011 and received conditional marketing.

FDA approved July 2014 for relapsed or refractory chronic lymphocytic leukemia (CLL) in combination with rituximab, relapsed small lymphocytic lymphoma.

Synonyms:

recidivism; reverting; lapse; relapsing; reversion; failure; lapsing; backsliding;

Antonyms:

gain; progress; precede; advance; tide;